Sandostatin is a somatostatin analog injection from Novartis used to suppress hormone secretion in acromegaly and neuroendocrine tumors.
Competing Products
Novartis
Innovative Swiss-American pharma creating transformative treatments.
Founded
2002Innovative Swiss-American pharma creating transformative treatments.
Founded in March 1996 through the merger of Ciba-Geigy and Sandoz, Novartis Institutes for BioMedical Research (NIBR) is a pioneering pharmaceutical research organization headquartered in Basel, Switzerland. NIBR's core mission is to transform patient care by focusing on unmet medical needs and advancing disease understanding. They specialize in developing innovative pharmaceutical drugs, generic drugs, and over-the-counter treatments. NIBR's unique approach integrates early-stage research with clinical practice to identify and advance the most promising drug candidates through Proof-of-Concept clinical trials.
Notable figures associated with Novartis include CEO Vasant Narasimhan and Chairman Jörg Reinhardt. The organization has achieved significant milestones in drug development and has a substantial impact on global healthcare. Novartis' commitment to innovation and patient-centric research has led to breakthroughs in various therapeutic areas, enhancing the quality of life for millions worldwide. Their work continues to set industry standards and drive advancements in pharmaceutical research and development.
Companies similar to Novartis include Amylyx Pharmaceuticals, Novartis Institutes For Biomedical Research, Novartis Pharma and Lonza.
Novartis was founded in 2002.
Novartis' headquarters is located in Basel, Basel-Stadt, CH.
Novartis' most recent funding round was for $6.5M (USD) in February 2018.
As of Feb 14, 2018, Novartis has raised a total of $6.5M (USD).
Novartis has 101,703 employees as of Feb 6, 2024.
Novartis Pharma